Media Contact:
Stephen Majors
Director, Public Affairs
smajors@alliancerm.org
Washington, DC
Created to address the underrepresentation of Black employees in the regenerative medicine workforce, the Alliance for Regenerative Medicine (ARM) launched the GROW RegenMed Internship Program this month with 17 interns in its inaugural class. GROW interns, who are undergraduate and graduate students, are working in paid positions at ARM and 13 of its member organizations this summer in a variety of roles, from the lab to regulatory affairs and public policy.
BRUSSELS, BELGIUM
Legislation approved by the German Parliament on 11 June would accelerate patient access to transformative cell and gene therapies by addressing a bureaucratic barrier that delayed their availability in hospitals.
The reduction of the “NUB gap” – advocated for by the Alliance for Regenerative Medicine (ARM), its member organizations, and the Association for German University Hospitals (VUD) – would enable NUB inquiries to occur twice a year for Advanced Therapy Medicinal Products (ATMPs) instead of just once. Inquiries could also be made before market authorization of a therapy.
BRUSSELS, BELGIUM
The European Commission should exempt advanced therapies from Genetically Modified Organism (GMO) legislation, which hurts Europe’s ability to attract clinical trials and delays patient access to transformative medicines, said the Alliance for Regenerative Medicine (ARM), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the European Association of Bioindustries (EuropaBio) in a paper published online yesterday in the journal Human Gene Therapy.
BRUSSELS, BELGIUM
The Alliance for Regenerative Medicine (ARM) – the global voice of the regenerative medicine and advanced therapies sector – welcomes the Council of the European Union’s support for EU-level joint clinical assessments. If adopted, joint clinical assessments can eliminate duplicative reviews of transformative Advanced Therapy Medicinal Products (ATMPs) across member states, reducing the time and cost required to bring durable, and potentially curative, cell, gene, and tissue-based therapies to patients anywhere in the EU.
